Spinal Cord Stimulation Market Report 2026

The spinal cord stimulation market size has grown strongly in recent years. It will grow from $3.41 billion in 2025 to $3.7 billion in 2026 at a compound annual growth rate (CAGR) of 8.5%. The growth in the historic period can be attributed to increase in chronic back pain cases, opioid alternatives demand, advancements in implantable electronics, growth in pain management clinics, favorable reimbursement policies.

The spinal cord stimulation market size is expected to see strong growth in the next few years. It will grow to $5.19 billion in 2030 at a compound annual growth rate (CAGR) of 8.8%. The growth in the forecast period can be attributed to ai-enabled stimulation optimization, expansion of indications beyond pain, technological miniaturization, rising geriatric population, long-term pain therapy adoption. Major trends in the forecast period include closed-loop stimulation systems, rechargeable implantable devices, personalized neuromodulation programming, outpatient implantation procedures, integration with digital pain monitoring.

The growing geriatric population is expected to drive the growth of the spinal cord stimulation market. Individuals aged 65 and above, commonly referred to as the geriatric population, have distinct healthcare and social needs associated with aging. As the number of older adults rises, the prevalence of ailments and chronic pain increases, leading to higher demand for spinal cord stimulation solutions and contributing to market expansion. For example, according to the World Health Organization, a US-based specialized health agency, by 2030, 1 in 6 people globally will be aged 60 or older, with the total number in this age group expected to double to 2.1 billion by 2050. Therefore, the rising geriatric population is fueling the growth of the spinal cord stimulation market.

Key companies in the spinal cord stimulation market are focusing on developing innovative products, such as spinal cord stimulation systems, to advance chronic pain therapy. A spinal cord stimulation system is a medical device that involves implanting electrodes along the spinal cord to relieve chronic pain. For instance, in March 2023, Nevro, a US-based medical device company specializing in chronic pain treatments, launched the HFX iQ Spinal Cord Stimulation System. This system leverages artificial intelligence to deliver personalized pain relief through real-time adjustments based on extensive clinical data. With features like the HFX algorithm and comprehensive pain management capabilities, it represents a significant advancement in spinal cord stimulation therapy, offering innovative, data-driven, and AI-powered solutions for individuals with chronic pain.

In November 2023, Nevro, a US-based medical device company for chronic pain, acquired VYRSA Technologies for $40 million upfront, with an additional $35 million in milestone payments. This acquisition strengthens Nevro’s presence in the spinal cord stimulation market by diversifying its product portfolio, expanding market reach, and addressing unmet medical needs in chronic pain management. VYRSA Technologies is a US-based medical technology company specializing in sacroiliac joint fusion.

Major companies operating in the spinal cord stimulation market are Abbott Laboratories,Medtronic PLC,Boston Scientific Corp.,LivaNova PLC,Globus Medical Inc.,ZimVie Inc.,Avanos Medical Inc.,Nevro Corp.,Saluda Medical Pty. Ltd.,Neuros Medical Inc.,Cirtec Medical Corp.,Mainstay Medical International plc,Gimer Medical,Stimwave Technologies,Vertiflex Inc.,SPR Therapeutics,Stimgenics Inc.,Axonics Modulation Technologies Inc.,Bioness Inc.,Nuvectra Corporation,Precision Spine Inc.,Vertiflex SCS Division.

North America was the largest region in the spinal cord stimulation market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the spinal cord stimulation market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the spinal cord stimulation market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have raised costs in the spinal cord stimulation market by increasing prices for imported implantable pulse generators, leads, microelectronics, and programming devices. Hospitals and ambulatory surgery centers in Asia-Pacific and Latin America are particularly affected due to dependence on global device manufacturers. These cost pressures can limit patient access to advanced neuromodulation therapies. At the same time, tariffs are encouraging domestic device manufacturing and component sourcing, strengthening long-term supply stability.

The spinal cord stimulation market research report is one of a series of new reports that provides spinal cord stimulation market statistics, including spinal cord stimulation industry global market size, regional shares, competitors with a spinal cord stimulation market share, detailed spinal cord stimulation market segments, market trends and opportunities, and any further data you may need to thrive in the spinal cord stimulation industry. This spinal cord stimulation market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Spinal cord stimulation is a relatively new approach for managing chronic pain when the underlying cause or damage cannot be fully treated. It works by delivering electrical pulses directly to the spinal cord to help control pain.

The main types of spinal cord stimulation products are rechargeable and non-rechargeable. Rechargeable refers to devices that can be recharged with electricity. Rechargeable spinal cord stimulators are used to treat persistent neuropathic pain following unsuccessful back surgery. They are applied in conditions such as failed back surgery syndrome (FBSS), degenerative disc disease (DDD), complex regional pain syndrome (CRPS), arachnoiditis, and others, and are utilized by end users including hospitals, ambulatory surgery centers, and specialty clinics.

The spinal cord stimulation market consists of sales of neurostimulators, leads, extensions, and handheld controllers. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.